Looking at the filing, I need to extract the key financial and operational data. The filing is a 10-Q for Boundless Bio, Inc. for the quarterly period ended September 30, 2026. The ticker is BOLD on the Nasdaq Global Select Market. Let me check the substantive disclosure content - there is enough content beyond boilerplate to proceed.

Boundless Bio, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the three-month period ended September 30, 2026, and disclosing a pending merger with Serapha Bio, Inc. as a central development.

Key Highlights

  • Shares outstanding: As of November 6, 2026, the registrant had 23,611,406 shares of common stock, $0.0001 par value per share, outstanding.
  • Pending merger: The company disclosed a potential merger with Serapha Bio, Inc., governed by a Merger Agreement, as a significant pending transaction.
  • Cash dividend: According to the filing, the anticipated cash dividend in connection with the merger may change based on timing to complete the merger, changes in operating expense levels, and other factors.
  • Reverse stock split: The filing disclosed a proposed reverse stock split as part of the merger transaction.
  • Company status: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Operating losses: The company disclosed it "has incurred significant operating losses since our inception and expects to incur significant losses for the foreseeable future."

Boundless Bio Discloses Serapha Bio Merger and ecDTx Pipeline Status

Boundless Bio, Inc. (NASDAQ:BOLD), a clinical-stage biopharmaceutical company based in La Jolla, California, filed its Form 10-Q for the quarterly period ended September 30, 2026 on November 10, 2026. The filing identifies the company's focus on extrachromosomal DNA (ecDNA) directed therapeutic candidates, which it refers to as ecDTx, and discloses a pending merger with Serapha Bio, Inc. as a material ongoing development.

According to the filing, the merger is subject to conditions including required stockholder approvals and regulatory and governmental consents. The filing cautioned that "failure to complete, or delays in completing, the potential Merger with Serapha Bio, Inc. could materially and adversely affect our results of operations, business, financial results and/or common stock price." The Exchange Ratio under the Merger Agreement "will not change or otherwise be adjusted based on the market price of our common stock," the company disclosed. The filing also noted that a proposed reverse stock split is part of the merger transaction.

On its pipeline, the company disclosed that its ecDTx candidates "have not achieved sufficiently favorable clinical results to date." The filing further noted that the company's "approach to treating cancer with oncogene amplifications by developing ecDTx directed against ecDNA is novel and unproven." The company stated it may require "substantial additional capital to finance our operations" if it continues ecDTx development, and that failure to obtain such capital "could force us to delay, limit, reduce or terminate any ecDTx development programs." The filing also noted the company "is currently a fully remote company and does not maintain physical offices."

What Was Disclosed

Boundless Bio filed its September 30, 2026 quarterly report disclosing a pending merger with Serapha Bio, Inc., a proposed reverse stock split, 23,611,406 shares outstanding as of November 6, 2026, and ongoing development of ecDNA-directed therapeutic candidates with no approved products.